Hemophagocytic Lymphohistiocytosis (HLH) is a hyperinflammatory disorder that may be encountered as a primary or secondary phenomenon. HLH secondary to lymphoma has been described, more frequently in adults than in children. T-cell/ Histiocyte-rich B-cell lymphoma (THRLBCL) is a large B-cell lymphoma that resides in a microenvironment of robust host immune response and has previously been associated with HLH in adults. Here, we describe the first case of HLH secondary to THRLBCL in an adolescent patient.
Introduction
Hemophagocytic Lymphohistiocytosis (HLH) is a lifethreating disorder characterized by qualitative deficiencies in cytotoxic lymphocytes, abnormal T-cell activation, and a hyperinflammatory state. 1 While often encountered as a primary genetic disorder, HLH also occurs as an acquired phenomenon, typically secondary to infection, rheumatologic disease, or malignancy. 2 Cancer-associated HLH is well described in adults and children, most frequently secondary to hematologic malignancies including lymphoma. Here, we report a case of T-cell/ Histiocyte-rich large B-cell lymphoma (THRLBCL), a rare subtype of diffuse large B-cell lymphoma (DLBCL), presenting as HLH in an adolescent patient.
Presentation
A 16-year-old boy presented with daily fevers, abdominal distension, and weight loss. Initial computed tomography (CT) imaging revealed multiple lung nodules, retroperitoneal and mesenteric lymphadenopathy, hepatosplenomegaly, and ascites. Mesenteric lymph node biopsy showed lymphocytic depletion with no evidence of malignancy, and peritoneal fluid analysis was unremarkable. Epstein-Barr Virus (EBV) DNA quantitative PCR of peripheral blood and EBV-specific antibodies (early antigen IgG, nuclear antigen IgG, viral capsid antigen IgM and IgG) were negative, indicating no ongoing or previous EBV infection. Two weeks after presentation, he developed multiple lab abnormalities (Figure 1(A) ). NK function was normal and a bone marrow evaluation showed hemophagocytosis without evidence of malignancy (Figure 1(B) ). He therefore met 7 of 8 diagnostic criteria for HLH per the 2004 Histiocyte Society guidelines. 3 Peripheral blood flow cytometry demonstrated no evidence of leukemia but decreased B-lymphocytes (3% of all lymphocytes), and a subset of CD3þCD8þ T-cells showed activation with expression of Human Leukocyte Antigen-antigen D Related (HLA-DR). Lymphocyte enumeration showed decreased absolute T-, B-, and NK-cells counts of 571, 19, and 55 cells/mL, respectively (normal ranges 1000-2200, 110-570, and 70-480 cell/mL).
Bronchoscopy with lung nodule biopsy demonstrated a nonspecific granulomatous process, and a serum IgG level was low at 349 gm/dL (641-1353 mg/dL). A culture from the bronchoscopy grew mycobacterium avium complex (MAC). He was given a working diagnosis of common variable immunodeficiency with opportunistic MAC infection. He began clarithromycin and ethambutol for MAC and methylprednisolone for presumed infectionassociated HLH. Once clinically improving, he was discharged on dexamethasone and cyclosporine with outpatient rheumatology follow-up.
He presented 2 weeks later with recurring fevers, and elevated ferritin (>40,000 ng/mL). Chemotherapy per HLH-2004 was initiated with 10 mg/m 2 /day dexamethasone and 150 mg/m 2 etoposide twice weekly 3 ; however, fevers persisted and ferritin remained elevated (>40,000 ng/mL) 30 days after initiation of therapy. Because of the patient's failure to respond to induction therapy, further imaging was performed to survey for occult malignancy. A repeat CT demonstrated cystic lung cavitations and worsening hepatosplenomegaly, now with discreet nodular masses, and a PET/CT demonstrated abnormal Fludeoxyglucose ( 18 F; FDG) uptake of the hepatic and splenic nodules. A repeat bronchial lavage sample culture revealed aspergillus fumigatus. He was started on voriconazole and a liver biopsy and repeat marrow studies were performed.
Diagnostic Findings
The liver biopsy demonstrated scattered large, atypical cells in a background comprised predominantly of small lymphocytes and histiocytes. The tumor cells did not form sheets and were positive for CD20, PAX5, CD30, and CD45 by immunohistochemistry (IHC). CD3 and CD68 stains demonstrated background T-lymphocytes and histiocytes, respectively (Figure 1(C) -(E)). Background lymphocytes essentially comprised CD3þ T lymphocytes, as small B lymphocytes are absent. The background T lymphocytes show a mix of CD4 and CD8 by IHC staining and show a CD4:CD8 ratio of 1-2:1. In situ hybridization for EBV (EBER) was negative in the neoplastic and nonneoplastic cells.
The bone marrow biopsy was hypocellular with focal areas of the marrow space showing large atypical cells that were positive for CD20 and PAX-5 with adjacent small lymphocytes and histiocytes. PET/CT revealed extensive disease with multifocal areas of abnormal FDG uptake throughout the skeleton, mass-like abnormal FDG uptake in the left lateral segment of the liver with background increased uptake throughout the liver, and nodular areas of FDG activity in the spleen (Figure 2(A) and 2(B) ).
Clinical Course
After the diagnosis of THRLBCL was confirmed, we initiated rituximab 375 mg/m 2 once weekly for 4 weeks, cyclophosphamide 750 mg/m 2 once, and resumed dexamethasone at 10 mg/m 2 /day. The patient became afebrile within 5 days of therapy initiation, and his transaminases and ferritin normalized within 4 weeks. He then received 2 courses of R-CHP (rituximab, cyclophosphamide, prednisone). An interval CT scan showed improving hepatosplenomegaly, and we then administered 2 courses of R- 
Discussion
HLH involves hyperactivation of CD8þ T-lymphocytes and macrophages, proliferation and infiltration of lymphocytes and histiocytes into normal tissue, and elevated proinflammatory cytokines, which may progress rapidly and result in organ toxicity and death. 4 While effective initial treatment for primary HLH is well established, 3, 5 appropriate treatment for secondary HLH is less well defined and must balance controlling inflammation with treating the underlying condition. In our patient initially treated with rituximab, cyclophosphamide, and steroids, which have efficacy in secondary HLH as well as lymphoma, 6 until more intensive lymphoma-specific therapy could be administered.
Malignancy-associated HLH may present prior to/ concurrently with the presentation of malignancy or after therapy initiation once the patient has become immunosuppressed. In adult case series, the proportion of secondary HLH comprised by malignancy-associated HLH varies greatly (6%-56%), and adults with a malignancy trigger had a poorer outcome than those triggered by infection. 7, 8 T-and NK-cell lymphomas are the most common causes of lymphoma-associated HLH in both children and adults; however, HLH in Hodgkin Lymphoma (HL) and non-Hodgkin B-cell lymphomas are also seen. 9, 10 THRLBCL represents a small subsection of DLBCL (1%-3% of cases) and shares similarities with nodular lymphocyte predominant hodgkin lymphoma on a histologic and genetic level, though THRLBCL is clinically aggressive compared to the more indolent nodular lymphocyte predominant hodgkin lymphoma. 11, 12 THRLBCL typically affects young adults with a male predominance and presents with liver, spleen, and bone marrow involvement more often than DLBCL. 13 Also unlike DLBCL, the neoplastic large B cells in THRLBCL do not form diffuse sheets and are separated by a prominent background of T lymphocytes and histiocytes. THRLBCL in children typically has limited stage involvement with good prognosis.
14 Three cases of THRLBCL-associated HLH have been published, with the youngest patient being 20 years old. 10, 15, 16 The diagnosis of a DLBCL variant in the setting of HLH and a questionable immunodeficiency also raises the question of an EBV-driven lymphoproliferative disorder (LPD). EBV infects approximately 90% of individuals worldwide, and is known to have an oncogenic role in the development of HL and non-Hodgkin B-cell lymphomas as well as LPDs associated with immunodeficiency (eg, posttransplant LPD and HIV-associated LPD). 17 Approximately 30% of HLH cases are viral infection- triggered, with EBV the most consistently reported. 18 However, our patient had no evidence of active or latent EBV infection, therefore excluding EBV-driven LPD as a diagnostic consideration.
Given that the tumor arises amidst an inflammatory infiltrate and our patient developed systemic HLH, this case of THRLBCL exemplifies the complexity of interaction between tumors and the immune system. THRLBCL are included in a broader subset of ''host response'' DLBCLs which have a gene signature consistent with ongoing inflammation, including enrichment of components of T cell receptors, complement cascade, and certain interferon-induced genes. These ''host response'' DLBCLs were also found to occur in younger patients and have a higher incidence of splenic and bone marrow involvement. 19 Specifically, tissue-associated macrophages in THRLBCL infiltrates demonstrate upregulation of pro-inflammatory factors and metal binding proteins. 20 Despite upregulation of the host inflammatory response, gene expression profiling of THRLBCL shows increased expression of IDO and VSIG4, which Van Loo et al. 21 speculate may induce immune tolerance of the neoplastic cells. Robust expression of the immune checkpoint regulator PD-L1 is seen in neoplastic B-cells and macrophages in THRLBCL, which may further induce tumor immune tolerance. 22 It remains to be determined if the upregulated host immune response is responsible for the HLH observed in our patient. It is also unsettled at this time if our patient has an underlying immunodeficiency such as common variable immunodeficiency which predisposed him to developing lymphoma. In conclusion, this case illustrates the intricatea interaction of the host immune system and malignancy, which is still incompletely understood. The case also demonstrates the need for vigilance in determining the underlying cause in cases of secondary HLH, which can alter the therapeutic approach.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.
